RU2326865C2 - Производные диарилметилиденпиперидина, способ их получения (варианты) и применение - Google Patents

Производные диарилметилиденпиперидина, способ их получения (варианты) и применение Download PDF

Info

Publication number
RU2326865C2
RU2326865C2 RU2005121490/04A RU2005121490A RU2326865C2 RU 2326865 C2 RU2326865 C2 RU 2326865C2 RU 2005121490/04 A RU2005121490/04 A RU 2005121490/04A RU 2005121490 A RU2005121490 A RU 2005121490A RU 2326865 C2 RU2326865 C2 RU 2326865C2
Authority
RU
Russia
Prior art keywords
phenyl
alkyl
methyl
compound
hydrogen
Prior art date
Application number
RU2005121490/04A
Other languages
English (en)
Other versions
RU2005121490A (ru
Inventor
Уиль м БРАУН (CA)
Уильям БРАУН
Эндрю ГРИФФИН (CA)
Эндрю Гриффин
Кристофер УОЛПОЛ (CA)
Кристофер Уолпол
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2005121490A publication Critical patent/RU2005121490A/ru
Application granted granted Critical
Publication of RU2326865C2 publication Critical patent/RU2326865C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к соединениям формулы I или к его фармацевтически приемлемым солям:
Figure 00000001
где R1 выбран из фенила, тиенила, фуранила и тиазолила; и R2, R3, R4 и R5 независимо выбраны из водорода и C1-6алкила. Изобретение также относится к применению и способам получения соединения формулы I, а также к соединениям формулы III. Технический результат - получение новых биологически активных соединений, обладающих активностью δ-агонистов. 5 н. и 7 з.п. ф-лы, 2 табл.

Description

Текст описания приведен в факсимильном виде.
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050

Claims (12)

1. Соединение формулы I или его фармацевтически приемлемая соль
где R1 выбран из фенила, тиенила, фуранила и тиазолила; и R2, R3, R4 и R5 независимо выбраны из водорода и С1-6алкила.
2. Соединение по п.1, где R2 и R3 представляют собой этил; R4 представляет собой С1-3алкил; и R5 представляет собой водород.
3. Соединение по п.1, где R2 и R3 независимо представляют собой этил; R4 представляет собой метил; и R5 представляет собой водород.
4. Соединение по п.1, выбранное из:
[3-[[4-[(диэтиламино)карбонил]фенил][1-(2-тиенилметил)-4-пиперидинилиден]метил]фенил]карбаминовой кислоты метилового эфира;
[3-[[4-[(диэтиламино)карбонил]фенил][1-(2-фуранилметил)-4-пиперидинилиден]метил]фенил]карбаминовой кислоты метилового эфира;
[3-[[4-[(диэтиламино)карбонил]фенил][1-(фенилметил)-4-пиперидинилиден]метил]фенил]карбаминовой кислоты метилового эфира;
метил-3-{{4-[(диэтиламино)карбонил]фенил}[1-(1,3-тиазол-4-илметил)-пиперидин-4-илиден]метил}фенилкарбамата;
метил-3-{{4-[(диэтиламино)карбонил]фенил}[1-(1,3-тиазол-5-илметил)-пиперидин-4-илиден]метил}фенилкарбамата;
и его фармацевтически приемлемые соли.
5. Соединение по любому из пп.1-4 для применения в изготовлении лекарства, обладающего активностью δ-агонистов.
6. Применение соединения по любому из пп.1-4 в изготовлении лекарства для лечения боли, тревоги или функциональных желудочно-кишечных расстройств.
7. Способ получения соединения формулы I
включающий взаимодействие соединения формулы II
Figure 00000052
с X-C(=O)-O-R4,
где X представляет собой Cl, Br или I;
R1 выбран из фенила, тиенила, фуранила и тиазолила; и
R2, R3, R4 и R5 независимо выбраны из водорода и С1-6алкила.
8. Соединение формулы III
Figure 00000053
где R2, R3, R4 и R5 независимо выбраны из водорода и C1-6алкила; и
R6 выбран из -Н и -С(=O)-O-C1-6алкила.
9. Способ получения соединения формулы I
включающий взаимодействие соединения формулы IV
Figure 00000054
с R1-CHO или R1CH2-x,
где Х представляет собой Cl, Br или I;
R1 выбран из фенила, тиенила, фуранила и тиазолила; и R2, R3, R4 и R5 независимо выбраны из водорода и C1-6алкила.
10. Способ по п.7, где R2 и R3 представляют собой этил; R4 представляет собой С1-3алкил; и R5 представляет собой водород.
11. Способ по п.9, где R2 и R3 представляют собой этил; R4 представляет собой С1-3алкил; и R5 представляет собой водород.
12. Соединение по п.8, где R2 и R3 представляют собой этил; R4 представляет собой С1-3алкил; и R5 представляет собой водород.
RU2005121490/04A 2003-01-16 2004-01-13 Производные диарилметилиденпиперидина, способ их получения (варианты) и применение RU2326865C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300103A SE0300103D0 (sv) 2003-01-16 2003-01-16 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0300103-9 2003-01-16

Publications (2)

Publication Number Publication Date
RU2005121490A RU2005121490A (ru) 2006-02-10
RU2326865C2 true RU2326865C2 (ru) 2008-06-20

Family

ID=20290138

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005121490/04A RU2326865C2 (ru) 2003-01-16 2004-01-13 Производные диарилметилиденпиперидина, способ их получения (варианты) и применение

Country Status (21)

Country Link
US (1) US20060116399A1 (ru)
EP (1) EP1587791A1 (ru)
JP (1) JP2006515356A (ru)
KR (1) KR20050096138A (ru)
CN (1) CN100430379C (ru)
AR (1) AR042886A1 (ru)
AU (1) AU2004203969B2 (ru)
BR (1) BRPI0406594A (ru)
CA (1) CA2510400A1 (ru)
IL (1) IL169360A0 (ru)
IS (1) IS7961A (ru)
MX (1) MXPA05007483A (ru)
NO (1) NO20053805L (ru)
NZ (1) NZ540759A (ru)
PL (1) PL378335A1 (ru)
RU (1) RU2326865C2 (ru)
SE (1) SE0300103D0 (ru)
TW (1) TW200427449A (ru)
UA (1) UA80310C2 (ru)
WO (1) WO2004063157A1 (ru)
ZA (1) ZA200505189B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0203301D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
US20070099957A1 (en) * 2003-05-16 2007-05-03 Astra Zeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
NZ546834A (en) 2003-10-01 2010-03-26 Adolor Corp Spirocyclic heterocyclic derivatives and methods of their use
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898339A (en) * 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) * 1983-07-27 1986-04-08 Janssen Pharmaceutica, N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
US4816586A (en) * 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5140029A (en) * 1989-01-09 1992-08-18 Janssen Pharmaceutica N.V. 2-aminopyrimidinone derivatives
US4939137A (en) * 1989-06-28 1990-07-03 Ortho Pharmaceutical Corporation Ring-fused thienopyrimidinedione derivatives
US5683998A (en) * 1991-04-23 1997-11-04 Toray Industries, Inc. Tricyclic triazolo derivatives, processes for producing the same and the uses of the same
US5574159A (en) * 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
TW548271B (en) * 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
AU2001241676A1 (en) * 2000-03-03 2001-09-17 Ortho-Mcneil Pharmaceutical, Inc. 3-(diarylmethylene)-8-azabicyclo(3.2.1)octane derivatives
US6556387B1 (en) * 2000-03-31 2003-04-29 Seagate Technology Llc Controlling mechanical response characteristics of a disc drive actuator by adjusting a fastener engaging the actuator shaft to vary axial force on the bearing assembly
SE0001207D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101766D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
SE0101765D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
BRPI0411998A (pt) * 2003-06-27 2006-09-05 Janssen Pharmaceutica Nv moduladores delta-opióides tricìclicos

Also Published As

Publication number Publication date
AU2004203969B2 (en) 2007-09-06
MXPA05007483A (es) 2005-12-05
IS7961A (is) 2005-07-27
SE0300103D0 (sv) 2003-01-16
US20060116399A1 (en) 2006-06-01
CN100430379C (zh) 2008-11-05
EP1587791A1 (en) 2005-10-26
AR042886A1 (es) 2005-07-06
IL169360A0 (en) 2007-07-04
WO2004063157A1 (en) 2004-07-29
RU2005121490A (ru) 2006-02-10
PL378335A1 (pl) 2006-03-20
NO20053805L (no) 2005-10-17
CA2510400A1 (en) 2004-07-29
NZ540759A (en) 2008-03-28
TW200427449A (en) 2004-12-16
JP2006515356A (ja) 2006-05-25
UA80310C2 (en) 2007-09-10
AU2004203969A1 (en) 2004-07-29
ZA200505189B (en) 2006-04-26
CN1735596A (zh) 2006-02-15
KR20050096138A (ko) 2005-10-05
BRPI0406594A (pt) 2005-12-20
NO20053805D0 (no) 2005-08-12

Similar Documents

Publication Publication Date Title
RU2436776C2 (ru) ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT
RU2007128085A (ru) Соли четвертичного аммония в качестве антагонистов м3
MA28097A1 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl] benzamide, leur preparation et leur application en therapeutique
JP2005508293A5 (ru)
RU2000129161A (ru) Производное 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способ его получения, фармацевтическая композиция, содержащая указанное соединение, и промежуточный продукт
JP2012510502A5 (ru)
RU2005104819A (ru) Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина
RU2219179C2 (ru) Азациклические соединения, фармацевтические композиции
RU2006130866A (ru) Новые спиропентациклические соединения
RU2324680C2 (ru) Производные диарилметилиденпиперидина, их применение, способы и промежуточное соединение для их получения
JP2006526608A5 (ru)
RU2007121222A (ru) Производные гидантоина, полезные в качестве ингибиторов металлопротеиназ
RU2326865C2 (ru) Производные диарилметилиденпиперидина, способ их получения (варианты) и применение
RU99120663A (ru) Замещенные бензамиды
WO2004060865A3 (en) N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines
RU2002133458A (ru) Соединения пиперазина и пиперидина
JP2005538111A5 (ru)
JP2005529164A5 (ru)
RU2005111985A (ru) Производные 4-(фенил-пиперазинил-метил)бензамида и их применение для лечения боли или желудочно-кишечных расстройств
MX2007006950A (es) Derivados de bis(fenil sustituido)-1-{[4-(heterociclil saturado-sustituido)fenilmetil]-(4-piperidil)}metano como insecticidas.
RU2005111983A (ru) Производные 4-(фенил-пиперазинил-метил)бензамида и их применение для лечения боли или желудочно-кишечных расстройств
RU2005128793A (ru) Химические соединения
CA2479362A1 (en) N-sulfonylurea apoptosis promoters
JP2005522481A5 (ru)
JP2005518363A5 (ru)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090114